Oh Young Bang/LinkedIn
Nov 9, 2025, 12:28
Oh Young Bang on Enhancement of Post-Stroke Neuroregeneration
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We’re confirming safety in stroke patients first, then moving on to drug-loaded exosome treatments for neurodegeneration (PMID: 40883738).
The BBB-bypass approach would be key.”
Read the full article here.
Article: Engineered MSC-EVs loaded with BDNF-enhancing neuropeptides via a non-disruptive method enhance post-stroke neuroregeneration via intranasal delivery
Authors: Ji-Eun Kim, Ye Eun Ji, Hyeon Jun Hwang, Ga-Eun Go, Hyung-Jun Lim, Jaein Yoo, Jooho Kim, Doil Park, Eun Hee Kim, Doory Kim, Oh Young Bang
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring